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COMMENTARIES
the war of nature, from famine and death, the most exalted object
which we are capable of conceiving, namely, the production of the
higher animals, directly follows. There is grandeur in this view of
life, with its several powers, having been originally breathed into a
few forms or into one; and that, while this planet has gone cycling
on according to the fixed law of gravity, from so simple a beginning
endless forms most beautiful and most wonderful have been, and are
being, evolved.3
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T

HE INFECTIOUS DISEASES SOCIETY OF AMERICA (IDSA)

issued updated clinical practice guidelines in 2006
for the diagnosis and treatment of Lyme disease.1
Within days, the Connecticut attorney general
launched an investigation, alleging IDSA had violated state
antitrust law by recommending against the use of longterm antibiotics to treat “chronic Lyme disease (CLD),” a
label applied by advocates to a variety of nonspecific symptoms for which frequently no evidence suggests the etiologic agent of Lyme disease is responsible. The IDSA was
forced to settle the claim to avoid exorbitant litigation costs,
even though the society’s guidelines were based on sound
science. The case exemplifies the politicization of health
policy, with elected officials advocating for health policies
against the weight of scientific evidence.

The Antitrust Investigation of IDSA
Although untreated or inadequately treated Lyme disease
can progress to cause neurological complications and arthritis, there is no evidence the disease has a chronic form
(except perhaps as sequelae) in the absence of objective clinical or serological evidence of active infection.2 Nevertheless, some patient groups and a small minority of physicians contend Borrelia burgdorferi, the causative agent of
Lyme disease, commonly persists in patients after standard
antibiotic treatments. They maintain that a constellation of
©2009 American Medical Association. All rights reserved.

nonspecific symptoms such as fatigue, myalgia, headaches, and chest pain are evidence of chronic infection, and
that standard diagnostics are inaccurate.3 Furthermore, some
recommend using long-term, high-dose antibiotics—
frequently administered intravenously—to treat patients with
nonspecific symptoms and no objective evidence of infection.3
The IDSA treatment guidelines strongly disagreed and instead labeled the constellation of symptoms “post-Lyme syndrome”—either sequelae without ongoing infection or unrelated to B burgdorferi. The guidelines state, “There is no
convincing biologic evidence for the existence of symptomatic chronic B burgdorferi infection among patients after
receipt of recommended treatment regimens for Lyme disease. Antibiotic therapy has not proven to be useful and is
not recommended for patients with chronic (ⱖ6 months)
subjective symptoms after recommended treatment regimens for Lyme disease.”1 The IDSA guidelines also rejected the use of a variety of alternative diagnostic tests
deemed unvalidated by the Centers for Disease Control and
Prevention (CDC) and US Food and Drug Administration.
IDSA’s guidelines were based on the biological implausibility of B burgdorferi persistence after proper treatment
in the absence of objective indications of treatment failure;
the high background rates of the subjective symptoms ofAuthor Affiliations: O’Neill Institute for National and Global Health Law, Georgetown University, Washington, DC.
Corresponding Author: Lawrence O. Gostin, JD, O’Neill Institute for National and
Global Health Law, Georgetown University, 600 New Jersey Ave NW, Washington, DC 20001 (gostin@law.georgetown.edu).
(Reprinted) JAMA, February 11, 2009—Vol 301, No. 6
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ten attributed to chronic Lyme infection; and the absence
of benefit from, and the serious adverse effects of, longterm treatment. The CDC4 and National Institutes of Health5
concurred in the judgment that long-term antibiotic use is
not justified: “despite extensive study, no clear evidence has
emerged to support the contention that CLD results from a
past or persistent Lyme disease infection.”5 American Academy of Neurology treatment guidelines for Lyme disease affecting the nervous system reached the same conclusion.6
The International Lyme and Associated Diseases Society
(ILADS), a CLD advocacy group, immediately protested and
asserted the superiority of its alternative guidelines,3 which
others have suggested were based on substandard review
methods.7 Shortly after, Connecticut Attorney General
Richard Blumenthal launched an investigation of IDSA’s
guideline writing process, alleging it violated state antitrust laws by excluding differing viewpoints from its guideline creation process and including members who had financial interests in, or ties to, Lyme diagnostic and treatment
makers.8 IDSA did disclose its panel members’ potential conflicts of interest in its published guidelines, even though there
is no evidence that any conflicts altered the guidelines’ content. Meanwhile, the committee that created the ILADS guidelines included the president of a company that manufactures an alternative Lyme disease diagnostic test9 and multiple
physicians whose practices are listed with a CLD advocacy
group’s patient referral service10—but ILADS did not disclose the conflicts in its guideline document.3
Antitrust laws are designed to ensure legitimate commercial competition and protect against predatory corporate practices due to inappropriate restraints on trade. Professional organizations, such as IDSA, can violate antitrust laws if their
standard-setting is an unreasonable attempt to advance their
members’ economic interests by suppressing competition.11
Applying the antitrust “rule of reason,” a challenger must show
that the professional organization both possesses substantial market power and that the anticompetitive effects of its
standards outweigh patient benefits.12 Even assuming IDSA
wielded sufficient market power through its nonbinding guidelines to meet the first part (which is questionable considering that insurers and clinicians can independently choose
which treatments to cover and prescribe), the second part of
the rule of reason cannot be met because IDSA guidelines substantially advanced patients’ interests.
The courts should defer to professional medical associations when standards are set on the basis of valid science
aimed at protecting patient health or safety. A precisely onpoint federal case (though one that does not bind Connecticut courts interpreting the state antitrust law) upheld the
American Academy of Ophthalmology guidelines attaching the label “experimental” to radial keratotomy, a surgical procedure for correcting nearsightedness.13 “Antitrust
law is about consumers’ welfare,” said the court, so ultimately professional guidelines are a “medical not a legal question.”13 That truism should decide antitrust cases, so that
666 JAMA, February 11, 2009—Vol 301, No. 6 (Reprinted)

when a professional organization bases its work on the weight
of science there can be no improper restraint of trade.
After spending more than a quarter of a million dollars
on legal expenses, IDSA agreed to settle with the attorney
general (without admitting any fault), assenting to an ombudsmen-reviewed panel to assess the 2006 guidelines.14
While it is unlikely IDSA’s guidelines will change due to the
investigation, the daunting potential for litigation by those
unhappy with the outcomes of treatment guidelines may well
chill the willingness of medical associations to make appropriate scientific evaluations of controversial topics—a development that would significantly threaten patient care and
increase medical costs.
Science, Values, and Politics
At the heart of this controversy is the conflict between the
positive nature of science and the normative function of value
systems and political thought. Science is, and can only be,
descriptive and explanatory. Whether a scientific finding is
judged to be accurate is dependent on the quality and rigor
of the methods used and whether that finding is replicable.
The scientific process is not democratic—no amount of desire for different results can establish them—and inconsistent findings create true controversy only when their methods are of comparable validity.
At the same time, the sciences cannot be normative. They
can establish context and a factual base for normative discourse, but scientific findings cannot entail any particular
normative conclusion without reference to outside systems of thought. Science, for example, cannot resolve the
never-ending debate over abortion in the United States. Medical science can describe the maternal health risks of pregnancy, elucidate fetal development, and establish risks of
birth defects and complications. Nothing, however, inherently follows from any of these; rather, policy makers must
look outside science, to moral, religious, ethical, and legal
norms—eg, when aggregated cells become human life or what
the relationship between citizens and their government
should be. Medical science can, and should, inform these
discussions, and in a vibrant and healthy society, such value
questions will be vigorously debated.
However, all too often, the normative and positive blend
into one another. Positive assertions are presented in a normative light—for example, that the cost of treating a condition surpasses a benchmark of cost-effectiveness, hence
it should not be used. This really consists of 3 separate assertions: the cost of treatment equals a particular amount
(a positive claim); treatments costing more than a certain
amount are not cost-effective; and cost-effectiveness should
guide the allocation of health care resources. All these claims
may be justifiable, but only the first can be established
through scientific methods.
The converse—when normative views are passed off as
positive assertions—is even more problematic, such as the
well-documented issue of abortion and breast cancer in the
©2009 American Medical Association. All rights reserved.
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Bush administration. Multiple adequately powered and welldesigned and analyzed studies investigated the putative association between abortion and breast cancer and found no
evidence of its existence. However, from 2002 to 2003, information was placed on the National Cancer Institute Web
site suggesting a link between abortion and breast cancer,
based largely on older epidemiologic studies that failed to
sufficiently control for recall bias.15
The Connecticut attorney general’s action against IDSA
falls into this latter category. The CLD advocacy community understandably seeks answers for the symptoms attributed to Lyme disease. But when high-quality research repeatedly was inconsistent with the group’s hypotheses, the
community should have sought other answers. Instead, many
advocacy organizations—and the attorney general—
insisted (against the weight of evidence) on a link between
the symptoms and chronic infection and continued to call
for long-term antibiotic treatments. Even this was perhaps
defensible—after all, medical studies cannot prove the nonexistence of a phenomenon—although physicians in the CLD
community should treat their patients based on the bestavailable evidence. But when political leaders using the force
of law sued IDSA for its appropriate scientific conclusions
that differed with the results they desired, they abused the
public good.
A wall of separation is needed between science, norms,
and politics. Science should inform normative discussions
and provide the evidentiary base for political choices. Likewise, values will always be important in deciding how science is applied for human benefit. But neither should be permitted to distort the other—limits on the outer boundaries
of what questions each can answer must be respected when
making public policy. Medical science, and the health of patients who depend on it, are too important to be subjected
to political ideologies.

©2009 American Medical Association. All rights reserved.
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